anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Ursodiol tablets, USP 250 mg are available as a film-coated tablet for oral administration. Ursodiol tablets, USP 500 mg are available as a scored film-coated tablet for oral administration. Ursodiol (ursodeoxycholic acid, UDCA) is a naturally occurring bile acid found in small quantities in normal human bile and in larger quantities in the biles of certain species of bears. It is a bitter-tasting white powder consisting of crystalline particles freely soluble in ethanol and glacial acetic acid, slightly soluble in chloroform, sparingly soluble in ether, and practically insoluble in water. The chemical name of ursodiol is 3α,7ß-dihydroxy-5ß-cholan-24-oic (C24H40O4). Ursodiol has a molecular weight of 392.56. Its structure is shown below.

Inactive ingredients: caprylic/capric triglycerides, copovidone, hypromellose, microcrystalline cellulose, magnesium stearate, povidone, polydextrose, polyethylene glycol 3350, sodium starch glycolate type A and titanium dioxide.
* LUPKYNIS capsules must be swallowed whole and must not be opened, crushed, or divided.
  * LUPKYNIS should be taken on an empty stomach consistently as close to a 12-hour schedule as possible, and with a minimum of 8 hours between doses.
  * If a dose is missed, instruct the patient to take it as soon as possible within 4 hours after missing the dose. Beyond the 4-hour time frame, instruct the patient to wait until the usual scheduled time to take the next regular dose. Instruct the patient not to double the next dose.
  * Instruct patients to avoid eating grapefruit or drinking grapefruit juice while taking LUPKYNIS [see Drug Interactions ( 7.1)] .
A 78-year-old woman without past relevant medical history presented to the emergency department for acute transient dysarthria. NIHSS was 0/42. Neurological examination revealed chorea-like movements over the left limbs, especially the foot. No other neurological signs were present. CT perfusion showed right cortical hypoperfusion due to right M2 occlusion, basal-ganglia perfusion was normal. Brain MRI revealed a small focus of restricted diffusion in the right insula, sparing basal ganglia. Based on the neuroimaging features and clinical correlation, despite the NIHSS score, we decided to treat the patient with alteplase, after iv-thrombolysis hyperkinetic movements ceased completely. Brain-MRI performed 72 h after symptom onset confirmed a confined insular ischemic lesion without the involvement of deep gray matter structures. Hyperkinetic movement disorders, such as hemichorea hemiballismus, are rare presentations of stroke, basal ganglia are mainly involved even if the insular cortex has been described too. Clinical decision on whether to treat ischemic stroke does not include movement disorders. Our case underscores NIHSS limitations in clinical practice.
Gut microbiota dysbiosis and gut barrier disruption are key events associated with high-fat diet (HFD)-induced systemic metabolic disorders. Gymnemic acid (GA) has been reported to have an important role in alleviating HFD-induced disorders of glycolipid metabolism, but its regulatory role in HFD-induced disorders of the gut microbiota and gut barrier function has not been elucidated. Here we showed that GA intervention in HFD-induced hamsters increased the relative abundance of short-chain fatty acid (SCFA)-producing microbes including Lactobacillus (P<.05) and Lachnoclostridium (P<.01) in the gut, and reduced the relative abundance of lipopolysaccharide (LPS)-producing microbes including Enterococcus (P<.05) and Bacteroides (P<.05), subsequently improving HFD-induced intestinal barrier dysfunction and systemic inflammation. Specifically, GA intervention reduced mRNA expression of inflammatory cytokines, including IL-1β, IL-6, and TNF-α (P<.01), increased mRNA expression of antioxidant-related genes, including Nfe2l2, Ho-1, and Nqo1 (P<.01), and increased mRNA expression of intestinal tight junction proteins, including Occludin and Claudin-1 (P<.01), thereby improving gut barrier function of HFD hamsters. This ameliorative effect of GA on the gut of HFD hamsters may further promote lipid metabolic balance in liver and adipose tissue by regulating the Toll-like receptor 4 (TLR4)-nuclear factor-κB (NF-κB) signaling pathway. Taken together, these results systematically revealed the important role of GA in regulating HFD-induced gut microbiota disturbance and gut barrier function impairment, providing a potential clinical theoretical basis for targeted treatment of HFD-induced microbiota dysbiosis.
Preoperative radiotherapy in locally advanced rectal cancer increases the possibility of complete resection and anal sphincter preservation. However, a treatment period of from 5 to 6 weeks is an obstacle of proper surgical intervention. Also, radiotherapy itself is confronting challenges for maximizing the therapeutic effect and minimizing the side effects. Electro-hyperthermia is appropriate treatment method to solve these kinds of problems. In this clinical trial, therapeutic effect of the high-frequency electro-hyperthermia is to be verified during preoperative radiotherapy for locally advanced rectal cancer. The endpoint of the trial is treatment safety and non-inferiority of tumor regression to conventional schedule of preoperative radiotherapy.
The present invention discloses a feed additive, particularly a compounding feed additive for pigs and a preparation technology thereof. The feed additive is prepared from core elements by the mass ratio: 4 to 6 parts of additive of Chinese herbal medicines, 2 to 4 parts of trace element and 1 to 3 parts of multiplex vitamin. The powdered additive is obtained by the refining processes of milling, stirring, extraction, etc. The feed additive is stirred with basal diet, and the basal diet and the feed additive are soaked to obtain incompact compound feed. The preparation technology comprises the step that a set of equipment is used for preparing powdery additive products of Chinese herbal medicines; the products are mixed with amino acid and trace elements so as to prepare a compounding product. The product prepared by the present invention has a high safety factor, and has the multiple functions of improving the disease resistance of pig bodies and increasing growth rate and feed utilization rate.
Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
PROBLEM TO BE SOLVED: To obtain the subject cosmetic having a controlled stickiness of a water-soluble L-ascorbic acid derivative, excellent sense of use and transparency by making the cosmetic include a specific modified dimethylpolysiloxane and the water-soluble L-ascorbic acid derivative and the content of an oil agent to a specific amount or smaller than it. SOLUTION: This cosmetic contains (A) a water-soluble polyether modified dimethylpolysiloxane having preferably >=10 HLB [one obtained by modifying a part of the methyl group of dimethylpolysiloxane with a polyether such as a (poly)oxyethylene and/or a (poly)oxypropylene, etc.], [e.g. SS-2,803 (trade name), etc.], (B) a water-soluble L-ascorbic acid derivative (e.g. sodium L- ascorbic acid phosphate) and (C) <=0.1 wt.% of an oil agent (a case in which an oil agent is not substantially contained is included). In the case, preferably the cosmetic contains 0.01-30 wt.% of the component A and 0.01-5 wt.% of the component B in the formulating ratio of the component A to the component B of preferably 1:0.1 to 1:10 by weight.
5 Chinese medicine prescription for treating venereal disease, syphilis, AIDS and SARS is disclosed. The Chinese medicine A is prepared from 10 Chinese-medicinal materials including honeysuckle flower, dandelion herb, etc. The Chinese medicine B is prepared from 10 Chinese-medicinal materials including green chiretta, isatis leaf, etc. The Chinese medicine C is garlicin. The Chinese medicine D is a chrysanthemum flower-sweet wormwood decoction. The Chinese medicine E is a polyose-ginseng-astragalus root mixture.
The BASICS + SLEEP intervention will integrate BASICS feedback and the Motivational Interviewing (MI) process described in the BASICS arm with Brief Behavioral Therapy for Insomnia (BBTI) content and materials. The BASICS + SLEEP intervention will be implemented in 2 sessions of 45-75 minutes and 2 telephone booster sessions. We will follow BBTI procedures, including provision of a physiological rationale for insomnia and the importance of behavioral strategies to regulate sleep; introduction of sleep hygiene; discussion of factors that can impede duration and quality of sleep; introduction of sleep restriction and stimulus control strategies and negotiation of an initial sleep restriction schedule; and follow-up evaluation of success and continued refinement to achieve sleep efficiency goals. Booster contacts serve as opportunities to adjust the sleep restriction schedule, problem-solve challenges, and further build motivation.
Methods, systems, and computer programs are presented for processing pregnancy care data for presentation via an information portal. The method includes accessing a plurality of data sources having care data related to a patient. The method includes filtering data from the plurality of data sources. The filtering is configured to identify relevant data to the patient responsive to a request for a guidance report for pregnancy care of the patient via the information portal. The method includes identifying at least one pattern from the relevant data. The method includes generating the guidance report regarding the patient. The guidance report includes relevant data from one or more prior visits with a care provider.
PROBLEM TO BE SOLVED: To make easily referable to the relative multimedia by providing a mark display means that shows the multimedia are related to record data and a reproduction means which reproduces the corresponding multimedia by designating a mark. SOLUTION: The home-visit nursing record data stored in a server 101 can be printed in an item-based time series list out of the server 101 by a printer 102. The bar code to be printed shows the specific data on a specific slip. The ID number of the slip and the index of the multimedia data corresponding to the ID number are recorded. The bar code is read by a bar code reader after the slip is printed and the data corresponding to the bar code are reproduced by a reproduction program corresponding to the data. Thus, it is possible to occasionally refer to the home-visit nursing record data and the multimedia data by means of the server 101 and an information reference device 103.
The invention comprises xanthoglabrol and its acyl derivatives, esters and salts, and the preparation thereof by a process wherein an acetic acid mother liquor remaining after crystallisation of a crude potassium salt of glycyrrhizin prepared from liquorice root is treated with a non-hydroxylic organic solvent, the precipitate so obtained freed from solvent, stirred with warm concentrated hydrochloric acid, water added and the total precipitate so obtained separated, dried, extracted with an ether and the ether finally removed.  The product may be acylated, or converted into salts with inorganic or organic bases (e.g. the sodium, piperazine, protamine and Nmethyl-glucamine salts).  Specification 843,134 is referred to.ALSO:Reddish azo-dyes are formed by coupling xanthoglabrol in alkaline solution with diazo compounds.  Xanthoglabrol is present as an ether-insoluble glycoside in liquorice root.  Specification 843,134 is referred to.ALSO:Pharmaceutical compositions comprise xanthoglabrol, alone or in admixture with one or more other active ingredients, and an inert liquid or solid carrier base.  The other active ingredients may be one or more analgesics, antibiotics, antiseptics, bacteriocides, bacteriostatics, chemotherapeutics, corticosteriods, fungicides, insecticides, keratolyticsor kerato plastics.  The compositions may take the form of an ointment, emulsion, lotion, suppository, dusting powder, injection, tablet, vaginal pessary or implant. Specification 843,134 is referred to.
The present invention is directed to a panel of monoclonal antibodies (Mabs) specific for murine prion protein PrPc. These Mabs can be applied to immunoblotting, cell surface immunofluorescent staining and immunohistochemistry at light and electron microscopy. Additionally, these Mabs recognize both the normal (PrPc) and protease-resistant (PrPres) isoforms of PrP. Some Mabs are species restricted, while others react with PrP from a broad range of mammals including mice, humans, monkeys, cows, sheep, squirrels and hamsters. Moreover, several of the Mabs selectively recognize different PrP glycoforms as well as the metabolic fragments of PrPc. These newly generated PrPc antibodies are useful for exploring the biology of PrPc and to establish the diagnosis of prion diseases in both humans and animals.
Patients receive yttrium Y 90 glass microspheres IA on day 0. Patients may receive additional treatment 4-12 weeks after initial treatment at the discretion of the study physician.
A no-laxation bulking system and a method for preparation of same is disclosed. Gelatin and pectin are combined to fro a dry-blended mixture. A second set of ingredients comprising modified polydextrose and erithritol is then blended to form a first liquid mixture. A second liquid mixture comprising at least one acid and water is formed. The dry-blended mixture is added to the first liquid mixture, forming a first combination. Water is added to the first combination, and the resultant combination is heated to a first predetermined temperature. The first predetermined temperature is maintained for a predetermined time period, and the heat is reduced to a second predetermined temperature. The second liquid mixture is added to the combination. Other embodiments comprise adding hydrogenated starch hydrolysate (HSH) and/or active ingredients. The second liquid mixture also may preferably include fruit concentrate, flavor, color and/or sucralose.
Crush the Crave (CTC) intervention group will receive a quit smoking smartphone intervention via the internet that is based on scientific findings related to tobacco use among young adults. It is a multi-component intervention informed by evidence on quitting smoking. The app was developed with the input of key experts in the field of smoking cessation, was assessed against Fiore's practice guidelines for treating tobacco use and dependence, and was tested with eight focus groups of male and female young adult smokers (n=57) on functionality, look and feel and usability, as well as being piloted by over 300 smokers.
Liver fibrosis is characterized by the activation of perivascular hepatic stellate cells (HSCs), the release of fibrogenic nanosized extracellular vesicles (EVs), and increased HSC glycolysis. Nevertheless, how glycolysis in HSCs coordinates fibrosis amplification through tissue zone-specific pathways remains elusive. Here, we demonstrate that HSC-specific genetic inhibition of glycolysis reduced liver fibrosis. Moreover, spatial transcriptomics revealed a fibrosis-mediated up-regulation of EV-related pathways in the liver pericentral zone, which was abrogated by glycolysis genetic inhibition. Mechanistically, glycolysis in HSCs up-regulated the expression of EV-related genes such as Ras-related protein Rab-31 (RAB31) by enhancing histone 3 lysine 9 acetylation on the promoter region, which increased EV release. Functionally, these glycolysis-dependent EVs increased fibrotic gene expression in recipient HSC. Furthermore, EVs derived from glycolysis-deficient mice abrogated liver fibrosis amplification in contrast to glycolysis-competent mouse EVs. In summary, glycolysis in HSCs amplifies liver fibrosis by promoting fibrogenic EV release in the hepatic pericentral zone, which represents a potential therapeutic target.
PURPOSE:To obtain an emulsified compsn. having excellent emulsification stability by incorporating >=1 or 2 kinds of phosphates of hydroxyalkyl or hydroxyalkenyl compds. expressed by the specific constitutional formulas. CONSTITUTION:The phosphate of hydroxyalkyl or hydroxyalkenyl compds. expressed by the formulaIand/or formula II (in the formula, R is the same or different and denotes an alkyl or alkenyl group respectively of 5-20 carbon atoms, X1, X2 denote the ion pair selected from the group consisting of hydrogen, alkali metals, ammonium, alkylammonium having alkyl groups of 1-5 carbon atoms, and alkanol amine having hydroxyalkyl groups of 2 or 3 carbon atoms) are compounded, whereby the emulsified compsn. is prepd.
Embodiments disclosed herein generally relate to a mental health platform for clinicians and patients. A computing system generates a plurality of sets of training data. The plurality of sets of training data include portions of journal and inputs to mental health questionnaires corresponding to a plurality of patients. The computing system generates a prediction model to generate a health score of a patient, the health score indicative of the current mental health of the patient. The computing system receives input from a target patient. The input includes target responses to mental health questionnaires and target journal entries. The computing system analyzes the journal entries using natural language processing to tag portions of the journal entry with semantic tone and sentiment indicators. The computing system generates, via the prediction model, a target health score for the target patient based on the target responses and the target journal entries.
Severe strokes, including large artery acute ischemic stroke and intracerebral hemorrhage, continue to be the leading cause of death and disability in adults in the U.S, accounting for more than 200,000 of the acute brain injury-related deaths in the U.S. annually. Patients with severe strokes are critically ill and most commonly require mechanical ventilation and supportive medical care with artificial nutrition to ensure survival. However, due to concerns for a poor long-term quality of life, withdrawal of mechanical ventilation and supportive medical care with transition to comfort care is by far the most common cause of death in severe strokes but occurs at a highly variable rate at different stroke centers. Shared decision making is a collaborative process that enhances patients' and surrogates' understanding about prognosis, encourages them to actively weigh the risks and benefits of a treatment, and to match them to patient preferences, thereby decreasing decisional conflict and improving decision quality and health related outcomes. Decision aids (DAs) are shared decision-making tools which have been successfully implemented and validated for many other diseases to assist difficult decision making. No DA currently exists for goals-of-care decisions in critically ill severe stroke patients. Such a patient- and family-centered DA has the potential to improve decision-making for critically ill severe stroke patients by ensuring proxies receive consistent, evidence-based prognostication while also addressing patients' preferences and values. The investigators have developed a pilot DA for goals of care decisions by surrogates of critically ill severe stroke patients using qualitative research using semi-structured interviews in surrogate decision makers of traumatic brain injury patients and physicians, followed by an iterative feedback process with feedback by surrogates, physicians, and other stakeholders (ICU nurses), and adaptation to large artery acute ischemic and hemorrhagic stroke. The investigators now propose to pilot-test a DA for surrogates of critically ill severe stroke patients in a feasibility trial.
Participants will use the closed loop system with insulin and pramlintide for managing blood sugar during the 12.5 hour study. Insulin and pramlintide will be administered by two Omnipods. Sensor glucose will be measured by a Dexcom G6 CGM. Participants will eat two meals while in clinic.
Clear aligners were ordered after the recordings were evaluated in the Clincheck program, and the final treatment plan was created. After the clear aligners came from the manufacturer (Align Technology, Santa Clara, CA), the compatibility of the guide aligner with each patient's mouth was checked for attachments. The enamel surfaces on which the attachments will be applied were etching with the same method as in Group A. After an adhesive was condensed into the attachment spaces inside the guide plate, the guide aligner was placed in the correct position in the mouth, and each attachment was applied from the buccal surface with an LED light device for 20 seconds. After the guide plate was removed, the composite residues around the attachments were cleaned, and the first treatment aligner was applied. The individuals were informed that they should use their clear aligner continuously, except during meals, and replace them after 10 days.
BACKGROUND: Chronic leg ulcers are hard to treat and can be a burden, particularly in resource-limited settings where diagnosis is a challenge. Staphylococcus aureus is among the common bacteria isolated from chronic wounds with a great impact on wound healing, particularly in patients with co-morbidities. Antimicrobial resistance genes and virulence factors in Staphylococcus aureus isolates were assessed to support healthcare professionals to make better therapeutic choices, and importantly to curb the development and spread of antibiotic resistance.
METHODS: A cross-sectional study involved both inpatients and outpatients with chronic leg ulcers was conducted from August 2022 to April 2023 in 2 health facilities in Kilimanjaro region in Tanzania. Antimicrobial susceptibility testing was done using the disk diffusion method. Further, whole genome sequencing was performed to study the genotypic characteristics of the isolates.
RESULTS: A total of 92 participants were recruited in which 9 participants were only positive for 10 Staphylococcus aureus isolates upon culture. Five STs among 9 isolates were identified. Most of them belonged to ST8 (44%), with 1 isolate does not belong to any ST. Additionally, 50% of the isolates were methicillin-resistant Staphylococcus aureus (MRSA). All S. aureus isolates had almost similar virulence factors such as hemolysin, proteases and evasions that promote toxin production, protease production and host immune evasion respectively. Moreover, all mecA positive S. aureus isolates were phenotypically susceptible to cefoxitin.
CONCLUSION: Presence of mecA positive S. aureus isolates which are also phenotypically susceptible to cefoxitin implies the possibility of classifying MRSA as MSSA. This may result in the possible emergence of highly cefoxitin - resistant strains in health care and community settings when subsequently exposed to beta-lactam agents. Therefore, combination of whole genome sequencing and conventional methods is important in assessing bacterial resistance and virulence to improve management of patients.